Loading...
Please wait, while we are loading the content...
Similar Documents
Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Svolos, Vaios Hansen, Richard Nichols, B. J. Quince, Christopher Ijaz, Umer Zeeshan Papadopoulou, Rodanthi Edwards, Christine Ann Watson, David G. Alghamdi, Adel Brejnrod, Asker Ansalone, Cecilia Duncan, Hazel Gervais, Lisa Tayler, Rachel Salmond, Jonathan M. Bolognini, Daniele Klopfleisch, Robert Gaya, Daniel R. Milling, Simon W. F. Russell, Richard K. Gerasimidis, Konstantinos |
| Copyright Year | 2019 |
| Abstract | BACKGROUND & AIMS Exclusive enteral nutrition (EEN) is the only established dietary treatment for Crohn's disease (CD), but its acceptability is limited. There is a need for novel dietary treatments for CD. METHODS We evaluated the effects of an individualized food-based diet (CD-TREAT), with similar composition to EEN, on the gut microbiome, inflammation, and clinical response in a rat model, healthy adults, and children with relapsing CD. Twenty-five healthy adults randomly received EEN or CD-TREAT for 7 days, followed by a 14-day washout period, followed by the alternate diet. Fecal microbiome and metabolome were assessed before and after each diet. HLA-B7 and HLA-B27 transgenic rats with gut inflammation received EEN, CD-TREAT, or standard chow for 4 weeks. Fecal, luminal, and tissue microbiome, fecal metabolites, and gut inflammation were assessed. Five children with active CD activity received CD-TREAT and their clinical activity and calprotectin were evaluated after 8 weeks of treatment. RESULTS For healthy adults, CD-TREAT was easier to comply with and more acceptable than EEN. CD-TREAT induced similar effects to EEN (EEN vs CD-TREAT) on fecal microbiome composition, metabolome, mean total sulfide (increase 133.0 ± 80.5 vs 54.3 ± 47.0 nmol/g), pH (increase 1.3 ± 0.5 vs 0.9 ± 0.6), and the short-chain fatty acids (μmol/g) acetate (decrease 27.4 ± 22.6 vs 21.6 ± 20.4), propionate (decrease 5.7 ± 7.8 vs 5.2 ± 7.9), and butyrate (decrease 7.0 ± 7.4 vs 10.2 ± 8.5). In the rat model, CD-TREAT and EEN produced similar changes in bacterial load (decrease 0.3 ± 0.3 log10 16S rRNA gene copies per gram), short-chain fatty acids, microbiome, and ileitis severity (mean histopathology score decreases of 1.25 for EEN [P = .015] and 1.0 for CD-TREAT [P = .044] vs chow). In children receiving CD-TREAT, 4 (80%) had a clinical response and 3 (60%) entered remission, with significant concurrent decreases in fecal calprotectin (mean decrease 918 ± 555 mg/kg; P = .002). CONCLUSION CD-TREAT replicates EEN changes in the microbiome, decreases gut inflammation, is well tolerated, and is potentially effective in patients with active CD. ClinicalTrials.gov, numbers NCT02426567 and NCT03171246. |
| Starting Page | 159 |
| Ending Page | 176 |
| Page Count | 18 |
| File Format | PDF HTM / HTML |
| DOI | 10.1053/j.gastro.2018.12.002 |
| PubMed reference number | 30550821 |
| Journal | Medline |
| Volume Number | 156 |
| Issue Number | 5 |
| Alternate Webpage(s) | http://eprints.gla.ac.uk/175003/10/175003.pdf |
| Alternate Webpage(s) | https://strathprints.strath.ac.uk/66547/1/Svolos_etal_Gastroenterology_2019_Treatment_of_active_crohns_disease_with_an_ordinary_food_based_diet.pdf |
| Journal | Gastroenterology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
